FDA's Got­tlieb out­lines new goals in bud­get plan, look­ing to spur drug re­views

Pres­i­dent Don­ald Trump’s bud­get sought a boost in fund­ing for the FDA and now FDA Com­mis­sion­er Scott Got­tlieb is of­fer­ing his own take on the ini­tia­tives and in­vest­ments the agency plans to pur­sue.

Plans out­lined by Got­tlieb in­clude the cre­ation of two new cen­ters re­lat­ed to drug com­pound­ing and dig­i­tal health.

Pro­mote Do­mes­tic Drug and Bi­o­log­ic Man­u­fac­tur­ing

As phar­ma­ceu­ti­cal and biotech com­pa­nies move to­ward ad­vanced man­u­fac­tur­ing tech­nolo­gies, such as con­tin­u­ous man­u­fac­tur­ing, Got­tlieb said vac­cine sup­plies can be “more eas­i­ly ramped up on short no­tice, and vac­cines them­selves adapt­ed over a short­er time pe­ri­od to ad­dress in­fec­tious dis­eases, such as the flu. The ap­pli­ca­tion of this kind of en­abling tech­nol­o­gy to vac­cine pro­duc­tion has long been a strate­gic pri­or­i­ty for the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER